Chronic cough treatment (implied by phase III trials)
Search documents
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate (NASDAQ:TRVI)
Seeking Alpha· 2025-11-14 02:22
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
